for the Period Ended 31 August 2024
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
for the Period Ended
2024 | 2023 | |
---|---|---|
|
£ |
£ |
Turnover: |
|
|
Cost of sales: |
(
|
(
|
Gross profit(or loss): |
|
|
Administrative expenses: |
(
|
(
|
Other operating income: |
|
|
Operating profit(or loss): |
( |
|
Interest payable and similar charges: |
(
|
(
|
Profit(or loss) before tax: |
( |
|
Profit(or loss) for the financial year: |
( |
|
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Current assets | |||
Debtors: | 3 |
|
|
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Creditors: amounts falling due after more than one year: | 4 |
(
|
(
|
Total net assets (liabilities): |
( |
( |
|
Capital and reserves | |||
Called up share capital: |
|
|
|
Profit and loss account: |
( |
( |
|
Total Shareholders' funds: |
( |
( |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 August 2024
Basis of measurement and preparation
for the Period Ended 31 August 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 August 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Other debtors |
|
|
Total |
|
|
for the Period Ended 31 August 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Other creditors |
|
|
Total |
|
|
We have set out on a journey to support cancer care, our focus is on providing empowering, targeted rehabilitation support to individuals facing colorectal, breast, and prostate cancer. Central to our mission is nurturing and uplifting the wellbeing of patients within the NHS and Beatson Cancer Charity community, we have supported over 100 people within our first year. With a proactive approach before, during, and after treatment, we guide patients towards smoother post-treatment recovery, easing the weight of care in the community. Through our compassionate efforts, we aim to improve treatment resilience, lessen healthcare demands, and sow the seeds for a brighter, healthier tomorrow for all those touched by cancer.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
28 April 2025
And signed on behalf of the board by:
Name: Ludovic Roy
Status: Director